Drugs that target the epidermal growth factor receptor (EGFR) have had a major impact on the treatment of non-small cell lung cancer (NSCLC). The use of these drugs has also motivated pivotal advances in the understanding of the molecular biology of NSCLC, including the discovery that mutations in EGFR are associated with dramatic and sustained responses to anti-EGFR treatments. This review summarizes the clinical development of EGFR tyrosine kinase inhibitors, the discovery of molecular predictors of response, and the future directions for research in the field.

中文翻译：

---

EGFR酪氨酸激酶抑制剂在肺癌中的作用：不断发展的故事。

靶向表皮生长因子受体（EGFR）的药物对非小细胞肺癌（NSCLC）的治疗产生了重大影响。这些药物的使用也促使人们对NSCLC分子生物学的理解取得了重要进展，包括发现EGFR突变与对抗EGFR治疗的显着且持续的反应相关。这篇综述总结了EGFR酪氨酸激酶抑制剂的临床发展，反应分子预测因子的发现以及该领域研究的未来方向。